UNSPSC 51401902: Alpidem

This classification denotes a sedative and hypnotic with the molecular formula C21H23Cl2N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I93SC245QZ, chemically known as 6-chloro-2-(p-chlorophenyl)-n,n-dipropylimidazo(1,2-a)pyridine-3-acetamide but generally known as alpidem, which bears US NIH Compound Identifier 54897. European Medicines Agency schedules Alpidem in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05367MIG.

UNSPSC 51401902 Alpidem is a Commodity code that encompasses pharmaceutical products and drug-related supplies procured by state and local health agencies, though recent opportunities under this code actually involve naloxone, generic pharmaceuticals, and over-the-counter products rather than alpidem specifically. State and local governments buying under this code include county health departments, state health and human services agencies, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions. Seminole County, Florida, for example, solicited naloxone and drug deactivation systems through an IFB, while the Texas Health and Human Services Commission issued an RFI to explore direct-to-manufacturer prescription programs, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities. These solicitations reflect procurement focused on community health support, emergency response supplies, and cost-effective pharmaceutical sourcing across government healthcare networks.

Recent activity appears concentrated in the South and Upper Midwest, with Seminole County, Florida; the Texas Health and Human Services Commission; and Minnesota's cooperative purchasing alliance all issuing or posting solicitations in the first half of 2026. Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually closed July 26, 2023, with quarterly deliveries required to the Seminole County Community Health Building in Sanford, Florida. The Texas HHS Commission's RFI on direct-to-manufacturer prescriptions, posted April 3, 2026, sought vendor capabilities for establishing relationships outside traditional pharmacy benefit manager and wholesaler channels. MMCAP's RFP for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, required vendors to supply through three authorized wholesalers with cGMP and Drug Supply Chain Security Act compliance, competitive pricing models, and performance penalties for late reporting or missed onboarding timelines. Vendors bidding under this code should expect insurance requirements, E-Verify compliance, federal regulatory adherence when FEMA funding is involved, and detailed product documentation including NDC codes and manufacturing information.